Paola Romagnani

@KSusztak Fantastic Katalin!

“Niches” Think of this like radiology for molecular biology. They define tissue neighborhoods that correlate with function: PT/DCT niches → better GFR Immune + injured PT niches → worse GFR This already beats crude histology.

🗞️📸🌟🤩Beautiful work led by @BernhardDumoul1 with the team builds a single cell spatial atlas of human DKD using Xenium + CosMx + snRNA-seq. @Nature This is not incremental. This is a new layer of pathology. Diabetic kidney disease (DKD) is still treated as one disease. That is the problem. Patients look similar clinically but behave very differently. We asked: is there a biologically distinct subgroup we are missing? rdcu.be/ff6ZZ

Congrats to @IsnardPierre1 and Marco Pontoglio HNF1B integrates signals in a feed-forward loop driving kidney disease progression | Happy to have contributed with Jon Levinsohn @ScienceMagazine science.org/doi/10.1126/sc…

🚨 Our new paper just dropped !!! Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes nature.com/articles/s4159…

@GlassockJ @ministeriosalud @ISNkidneycare Three decades of antihypertensive drugs used worldwide to control blood pressure—yet the rate of “hypertension-related CKD”diagnoses in international registries hasn’t changed. Doesn’t that tell us something?

@ministeriosalud @ISNkidneycare Does better BP control truly “prevent” CKD? If so what is the evidence and what are the appropriate goal to optimize prevention and minimize adverse effects. ?

La enfermedad renal crónica es un problema de salud pública relevante que puede prevenirse y detectarse a tiempo. Cuidar la salud renal es clave para mantener una buena calidad de vida a lo largo de los años. 💧 Mantener hábitos saludables, controlar factores de riesgo como la hipertensión o la diabetes, y realizar chequeos médicos periódicos puede marcar la diferencia.

JASN Editors’ Choice 2025: Piezo1, F-Actin Remodeling, and Podocyte Survival and Regeneration This study demonstrated that Piezo1 is essential for the survival of podocytes exposed to mechanical stress conditions and for their correct regeneration. Check out the paper: kidney.pub/JASN0697

Our study "Piezo1, F-actin, and podcyte survival and regeneration" has been selected by the ASN editorial team for inclusion in their 2025 JASN-themed highlight edition. @MarEleMelica @PRomagnani @GiuAntonelli12 @AnnaPeired @ElenaLazzeri2 @letiziadechiara @CarolinaConte5

When is Genetic Testing Needed in Glomerular Disease? Check out this perspective in #ASNCJASN kidney.pub/CJASN0964

@diego_moriconi 😆agree!

@PRomagnani No one blinks when a nephrology tells a patient "you have FSGS". But imagine a dermatology saying "you have papules". Histology is a means, not the end. #nephrology #histology #precisionmedicine #etiology

In Podocytopathies, histology labels lesions—etiology dictates therapy. Time for an etiology-based classification. Our new review just out in Nat Rev Dis Primers: nature.com/articles/s4157… #Nephrology #PrecisionMedicine #KidneyDisease

Happy to share our new Nat Rev Dis Primer on Podocytopathies @DiseasePrimers including all most recent innovations that impact on management such as anti-nephrin antibodies, ... @PRomagnani @Tobias_B_Huber @AstridWeins @sydney_tang rdcu.be/eUG2t

Everything you need to know about podocyte disorders @DiseasePrimers @PRomagnani, @Tobias_B_Huber, @AstridWeins, @sydney_tang rdcu.be/eUG2t

@KSusztak @CircAHA Congrats Katalin!

🚨 Just out from our lab in @CircAHA! 🚨 We know APOL1 risk variants (RVs) cause FSGS. But what about Hypertension-Attributed Kidney Disease (H-CKD)? 🤔 H-CKD is distinct: slowly progressing, low albuminuria, and massive vascular damage. Is it just secondary to kidney injury? Or is it a primary vascular defect? We found the answer.🧵👇ahajournals.org/eprint/TNWJK5I…

@WashUNephrology @HumphreysLab @ASNKidney @WashUDeptMed Congrats Ben!

Proud to celebrate our Chief, Dr. Benjamin Humphreys (@HumphreysLab) on his appointment to the @ASNKidney Executive Council - on track to serve as ASN president in 2028! @WashUNephrolgy @WashUDeptMed nephrology.wustl.edu/benjamin-humph…

Now out in @JASN_News @StefanieSteige6 @PRomagnani How to Cure Autoimmune GN and podocytopathies 🧐 All autoimmune kidney diseases, no matter what histotype or clinical presentation, benefit from a clone-directed immunotherapy. ▶️journals.lww.com/jasn/abstract/…

Now online in the Journal of the American Society of Nephrology: How to cure glomerulonephritis and podocytopathies? ⁦@PRomagnani⁩ ⁦@StefanieSteige6⁩ journals.lww.com/jasn/abstract/…

Celebrating the Nobel for Tregs brings me back to my youth— to the cells that taught us tolerance, and my father who taught me immunology and the wonder of research. Here’s when we found Treg in the human thymus 23 yrs ago. pmc.ncbi.nlm.nih.gov/articles/PMC21…

Anti-nephrin antibodies in patients with IgA nephropathy and nephrotic syndrome | Nephrology Dialysis Transplantation | Oxford Academic academic.oup.com/ndt/advance-ar…

@valerie_luyckx @gunnar_heine @NDTsocial @fcaravacafontan @fervenzafernan1 @willkidney Totally agree! In children and adolescents

@PRomagnani @gunnar_heine @NDTsocial @fcaravacafontan @fervenzafernan1 @willkidney This is a concern in expecting benefits in children…my ow observations a bit underwhelming…we need data in children urgently

No antiproteinuric effect of SGLT2-inhibitors in non-diabetic glomerulopathies & normal BMI? A @NDTsocial cohort by @fcaravacafontan @PRomagnani @fervenzafernan1 BUT: In @willkidney's EMPA-KIDNEY RCT, CKD pat with normal BMI DID benefit from EMPA academic.oup.com/ndt/article/do…

@gunnar_heine @NDTsocial @fcaravacafontan @fervenzafernan1 @willkidney Unlike EMPA (46% diabetes, 78.6% GFR<45, mean BMI 29.7), our study excluded diabetes, mean GFR>50. Here, only overweight/obesity explained hypervolemia. In pts without this factor, SGLT2i had no effect. Explained in more detail in doi.org/10.1093/ndt/gf…

@gunnar_heine @NDTsocial @fcaravacafontan @fervenzafernan1 @willkidney In EMPA, 46.2% had diabetes, mean BMI 29.7, and 78.6% had GFR <45. Thus, in EMPA pts with BMI <25 had other reasons for hypervolemia. EMPA or its meta-analyses cannot draw conclusions for pts with BMI <25, no diabetes and GFR >60—this subgroup wasn’t powered